Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Buy
51
ACTU Quote, Financials, Valuation and Earnings
Last price:
$7.34
Seasonality move
:
-23.17%
Day range:
$7.30 - $7.64
52-week range:
$5.47 - $11.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
15.62x
Volume:
57.1K
Avg. volume:
52.1K
1-year change:
-16.1%
Market cap:
$170.8M
Revenue:
--
EPS (TTM):
-$1.21
Analysts' Opinion
-
Consensus RatingActuate Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $25.03, Actuate Therapeutics, Inc. has an estimated upside of 240.54% from its current price of $7.35.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $20.00 representing 100% downside risk from its current price of $7.35.
Fair Value
-
According to the consensus of 4 analysts, Actuate Therapeutics, Inc. has 240.54% upside to fair value with a price target of $25.03 per share.
ACTU vs. S&P 500
-
Over the past 5 trading days, Actuate Therapeutics, Inc. has underperformed the S&P 500 by -3.97% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Actuate Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Actuate Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Actuate Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Actuate Therapeutics, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Actuate Therapeutics, Inc. reported earnings per share of -$0.25.
Enterprise value:
154.3M
EV / Invested capital:
13.61x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-7.62x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-228.64%
Net Income Margin (TTM):
--
Return On Equity:
-1392.96%
Return On Invested Capital:
-1128.92%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -$25.1M | -$24.4M | -$5.4M | -$5.5M | |
| EBITDA | -- | -$25.1M | -$24.4M | -$5.4M | -$5.5M | |
| Diluted EPS | -$0.88 | -$1.40 | -$1.21 | -$0.31 | -$0.25 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | $14.3M | $17.4M | |
| Total Assets | -- | -- | -- | $14.3M | $17.7M | |
| Current Liabilities | -- | -- | -- | $8.5M | $6.4M | |
| Total Liabilities | -- | -- | -- | $8.9M | $6.8M | |
| Total Equity | -- | -- | -- | $5.4M | $10.9M | |
| Total Debt | -- | -- | -- | $405K | $405K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$22.6M | -$20.2M | -$9M | -$6.5M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | $27.6M | $23.6M | $22.1M | $16.9M | |
| Free Cash Flow | -- | -$22.6M | -$20.2M | -$9M | -$6.5M | |
ACTU
Sector
Market Cap
$170.8M
$28.5M
Price % of 52-Week High
61.3%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-14.49%
-1.33%
1-Year Price Total Return
-16.1%
-20.32%
Beta (5-Year)
--
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$7.18
200-day SMA
Sell
Level
$7.62
Bollinger Bands (100)
Buy
Level
6.4 - 7.96
Chaikin Money Flow
Sell
Level
-42.2K
20-day SMA
Buy
Level
$6.51
Relative Strength Index (RSI14)
Buy
Level
60.12
ADX Line
Buy
Level
24.68
Williams %R
Neutral
Level
-20.0735
50-day SMA
Buy
Level
$6.87
MACD (12, 26)
Buy
Level
0.18
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Neutral
Level
761.7K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-18.623)
Sell
CA Score
(Annual)
Level (-23.1755)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (21.3966)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.
Stock Forecast FAQ
In the current month, ACTU has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ACTU average analyst price target in the past 3 months is $25.03.
-
Where Will Actuate Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Actuate Therapeutics, Inc. share price will rise to $25.03 per share over the next 12 months.
-
What Do Analysts Say About Actuate Therapeutics, Inc.?
Analysts are divided on their view about Actuate Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Actuate Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $20.00.
-
What Is Actuate Therapeutics, Inc.'s Price Target?
The price target for Actuate Therapeutics, Inc. over the next 1-year time period is forecast to be $25.03 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ACTU A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Actuate Therapeutics, Inc. is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ACTU?
You can purchase shares of Actuate Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Actuate Therapeutics, Inc. shares.
-
What Is The Actuate Therapeutics, Inc. Share Price Today?
Actuate Therapeutics, Inc. was last trading at $7.34 per share. This represents the most recent stock quote for Actuate Therapeutics, Inc.. Yesterday, Actuate Therapeutics, Inc. closed at $7.35 per share.
-
How To Buy Actuate Therapeutics, Inc. Stock Online?
In order to purchase Actuate Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get ACTU Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ACTU
Sector
P/E ratio
--
23.75x
PEG ratio
--
-0.01x
P/B ratio
15.62x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
ACTU
Sector
Revenue growth
--
4.85%
Earnings growth
17.34%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.28
-$0.20
Profitability
ACTU
Sector
Profitability FY 2024
--
$3.6M
Return on invested capital
-1128.92%
-30.98%
Return on assets
-228.64%
-27.62%
Return on equity
-1392.96%
-36.69%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
31
Estimated Next Earnings Date
Feb
12
Balance Sheet
ACTU
Sector
Total cash
$16.9M
$27.2M
Short term investments
--
$25.7M
Total assets
$9.3M
$79.7M
Long term debt
$405K
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
